Cibus (CBUS) 10-Q 5 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 05, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Trading Symbol	CLXT
Entity Registrant Name	Calyxt, Inc.
Entity Central Index Key	0001705843
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		37,065,044
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-38161
Entity Tax Identification Number	27-1967997
Entity Address, Address Line One	2800 Mount Ridge Road
Entity Address, City or Town	Roseville
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55113-1127
City Area Code	651
Local Phone Number	683-2807
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock (0.0001 par value)
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 7,170	$ 58,610
Short-term investments	20,802
Restricted cash	393	388
Accounts receivable	2,432	1,122
Due from related parties	2
Inventory	5,953	2,594
Prepaid expenses and other current assets	1,515	808
Total current assets	38,267	63,522
Non-current restricted cash	1,041	1,040
Land, buildings, and equipment	22,823	23,212
Other non-current assets	347	324
Total assets	62,478	88,098
Current liabilities:
Accounts payable	1,163	1,077
Accrued expenses	4,261	2,544
Accrued compensation	1,609	2,181
Due to related parties	481	977
Current portion of financing lease obligations	361	356
Other current liabilities	44	61
Total current liabilities	7,919	7,196
Financing lease obligations	18,022	18,244
Long-term debt	1,518
Other non-current liabilities	123	150
Total liabilities	27,582	25,590
Stockholders’ equity:
Common stock, $0.0001 par value; 275,000,000 shares authorized; 33,343,313 shares issued and 33,243,161 shares outstanding as of September 30, 2020, and 33,033,689 shares issued and 32,951,329 shares outstanding as of December 31, 2019	3	3
Additional paid-in capital	189,437	185,588
Common stock in treasury, at cost; 100,152 shares as of September 30, 2020, and 82,360 shares as of December 31, 2019	(1,043)	(1,043)
Accumulated deficit	(153,498)	(122,057)
Accumulated other comprehensive income (loss)	(3)	17
Total stockholders’ equity	34,896	62,508
Total liabilities and stockholders’ equity	$ 62,478	$ 88,098

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	275,000,000	275,000,000
Common stock, shares issued	33,343,313	33,033,689
Common stock, shares outstanding	33,243,161	32,951,329
Treasury stock, shares	100,152	82,360

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenue	$ 5,241	$ 2,967	$ 9,925	$ 3,533
Cost of goods sold	7,060	3,528	16,265	3,865
Gross margin	(1,819)	(561)	(6,340)	(332)
Operating expenses:
Research and development	2,204	3,579	7,816	8,536
Selling and supply chain	439	1,314	3,368	3,421
General and administrative	4,185	4,934	12,713	14,302
Management fees	68	305	172	1,117
Restructuring costs	436		436
Total operating expenses	7,332	10,132	24,505	27,376
Loss from operations	(9,151)	(10,693)	(30,845)	(27,708)
Interest, net	(324)	32	(568)	296
Foreign currency transaction loss	(1)	(8)	(28)	(35)
Loss before income taxes	(9,476)	(10,669)	(31,441)	(27,447)
Income taxes	0	0	0	0
Net loss	$ (9,476)	$ (10,669)	$ (31,441)	$ (27,447)
Basic and diluted net loss per share	$ (0.29)	$ (0.32)	$ (0.95)	$ (0.84)
Weighted average shares outstanding - basic and diluted	33,200,289	32,866,467	33,076,376	32,759,194

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDER'S EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Shares in Treasury [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning balance at Dec. 31, 2018	$ 93,397	$ 3	$ 176,069	$ (230)	$ (82,445)
Beginning balance, shares at Dec. 31, 2018		32,648,893
Net loss	(27,447)				(27,447)
Stock based compensation	6,565		6,565
Stock based compensation, shares		261,883
Issuance of common stock	314		314
Shares withheld for net share settlement	(645)			(645)
Shares withheld for net share settlement, shares		(43,363)
Other comprehensive income (loss)	(55)					$ (55)
Ending balance at Sep. 30, 2019	72,129	$ 3	182,948	(875)	(109,892)	(55)
Ending balance, shares at Sep. 30, 2019		32,867,413
Beginning balance at Jun. 30, 2019	80,190	$ 3	180,237	(789)	(99,223)	(38)
Beginning balance, shares at Jun. 30, 2019		32,859,700
Net loss	(10,669)				(10,669)
Stock based compensation	2,705		2,705
Stock based compensation, shares		7,713
Issuance of common stock	6		6
Shares withheld for net share settlement	(86)			(86)
Other comprehensive income (loss)	(17)					(17)
Ending balance at Sep. 30, 2019	72,129	$ 3	182,948	(875)	(109,892)	(55)
Ending balance, shares at Sep. 30, 2019		32,867,413
Beginning balance at Dec. 31, 2019	62,508	$ 3	185,588	(1,043)	(122,057)	17
Beginning balance, shares at Dec. 31, 2019		32,951,329
Net loss	(31,441)				(31,441)
Stock based compensation	3,638		3,638
Stock based compensation, shares		309,624
Issuance of common stock	211		211
Shares withheld for net share settlement, shares		(17,792)
Other comprehensive income (loss)	(20)					(20)
Ending balance at Sep. 30, 2020	34,896	$ 3	189,437	(1,043)	(153,498)	(3)
Ending balance, shares at Sep. 30, 2020		33,243,161
Beginning balance at Jun. 30, 2020	43,553	$ 3	188,656	(1,043)	(144,022)	(41)
Beginning balance, shares at Jun. 30, 2020		33,040,520
Net loss	(9,476)				(9,476)
Stock based compensation	570		570
Stock based compensation, shares		202,641
Issuance of common stock	211		211
Other comprehensive income (loss)	38					38
Ending balance at Sep. 30, 2020	$ 34,896	$ 3	$ 189,437	$ (1,043)	$ (153,498)	$ (3)
Ending balance, shares at Sep. 30, 2020		33,243,161

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating activities
Net loss	$ (31,441)	$ (27,447)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization	1,372	1,051
Stock-based compensation	3,638	6,565
Changes in operating assets and liabilities:
Accounts receivable	(1,310)	(1,304)
Due to/from related parties	(498)	(1,223)
Inventory	(3,359)	(2,371)
Prepaid expenses and other current assets	(707)	192
Accounts payable	86	127
Accrued expenses	1,717	(49)
Accrued compensation	(572)	478
Other current liabilities	(64)	(743)
Other non-current assets	140	36
Net cash used by operating activities	(30,998)	(24,688)
Investing activities
Purchases of land, buildings, and equipment	(1,146)	(2,538)
Short-term investments	(20,802)
Net cash used by investing activities	(21,948)	(2,538)
Financing activities
Proceeds from Payroll Protection Program loan	1,518
Repayments of financing lease obligations	(217)	(195)
Proceeds from the exercise of stock options	211	314
Costs incurred related to shares withheld for net share settlement		(645)
Proceeds from the sale and leaseback of land, buildings, and equipment		414
Net cash provided (used) by financing activities	1,512	(112)
Net decrease in cash, cash equivalents and restricted cash	(51,434)	(27,338)
Cash, cash equivalents and restricted cash - beginning of period	60,038	95,288
Cash, cash equivalents and restricted cash – end of period	$ 8,604	$ 67,950

Basis of Presentation & Summary

Basis of Presentation & Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation & Summary of Significant Accounting Policies	1. BASIS OF PRESENTATION & SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Our unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP or GAAP) for interim financial information and with the rules and regulations of the Securities and Exchange Commission (SEC) applicable to interim financial statements. In our opinion, the accompanying consolidated financial statements reflect all adjustments necessary for a fair presentation of our statements of financial position, results of operations and cash flows for the periods presented but they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Except as otherwise disclosed herein, these adjustments consist of normal recurring items. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole or any other interim period. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the consolidated financial statements and during the reporting period. Actual results could materially differ from these estimates. Certain prior year amounts have been reclassified to conform to the current year presentation. For further information, refer to the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 5, 2020. The accompanying Balance Sheet as of December 31, 2019, was derived from the audited consolidated financial statements. This Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and notes included in the Annual Report on Form 10-K for the year ended December 31, 2019. Short-term investments We consider investments with more than ninety days to maturity at issuance to be short-term investments. These short-term investments are considered trading securities and are carried at fair value with any unrealized gains and losses recorded in current earnings as a component of interest, net. Revenue Recognition In certain instances, we may sell grain to a processor with a commitment to repurchase any soybean meal resulting from their grain crushing activity with a single net cash settlement occurring between the parties. In those instances, we recognize revenue from the sale of grain in the amount of the final net cash settlement with the processor. We also recognize revenue on our sale of the meal to our customers in accordance with our previously disclosed revenue recognition accounting policies. Costs are ascribed to grain and meal sold pursuant to the agreement with the processor.

Financial Instruments, Measured

Financial Instruments, Measured at Fair Value, Hedging Activities, and Concentrations of Credit Risk	9 Months Ended
	Sep. 30, 2020
Text Block [Abstract]
Financial Instruments, Measured at Fair Value, Hedging Activities, and Concentrations of Credit Risk	2. FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE, HEDGING ACTIVITIES, AND CONCENTRATIONS OF CREDIT RISK Financial Instruments Measured at Fair Value and Financial Statement Presentation Financial instruments including cash and cash equivalents, restricted cash, due from related parties, accounts payable, due to related parties and all other current liabilities have carrying values that approximate fair value. We measure short-term investments and commodity derivative contracts at fair value on a recurring basis. The accounting guidance establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as of the measurement date as follows: Level 1: Fair values are based on unadjusted quoted prices in active trading markets for identical assets and liabilities. Level 2: Fair values are based on observable quoted prices other than those in Level 1, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets. Level 3: Fair values are based on at least one significant unobservable input for the asset or liability. Fair Value Measurements and Financial Statement Presentation The fair values of our financial instruments measured at fair value and their respective levels in the fair value hierarchy as of September 30, 2020, and December 31, 2019, were as follows: September 30, 2020 September 30, 2020 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Short-term investments $ 20,802 $ — $ — $ 20,802 $ — $ — $ — $ — Commodity derivative contracts 132 — — 132 — — — — Total $ 20,934 $ — $ — $ 20,934 $ — $ — $ — $ — December 31, 2019 December 31, 2019 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Commodity derivative contracts $ 62 $ — $ — $ 62 $ — $ — $ — $ — Total $ 62 $ — $ — $ 62 $ — $ — $ — $ — The non-current portion of our financing lease obligations are also considered a financial instrument, which we measure at fair value for disclosure purposes. It is a Level 2 liability and had a fair value of $15.2 million as of September 30, 2020, and a fair value of $15.7 million as of December 31, 2019. The composition of our short-term investments as of September 30, 2020, and December 31, 2019 were as follows: As of September 30, As of December 31, In Thousands 2020 2019 Corporate debt securities $ 17,803 $ — Commercial paper 2,999 — Total $ 20,802 $ — Commodity Price Risk We enter into seed and grain production agreements (Forward Purchase Contracts) with settlement values based on commodity futures market prices. These Forward Purchase Contracts allow the counterparty to fix their sales prices at various times as defined in the contract. Because we intend to take physical delivery under the Forward Purchase Contracts, we have grain inventory we will need to sell. We intend to sell these inventories at then-current market prices. As a result, when the Forward Purchase Contract counterparty fixes their grain prices, we enter hedging arrangements by selling futures contracts which converts our exposure to these fixed prices to floating prices. We expect to maintain these hedging relationships until such grain inventory is sold to help stabilize our margins. We do not account for these economic hedges as accounting hedges. We expect any gains or losses from these hedging arrangements to be offset by gains or losses on the grain inventories when such grain inventories are sold. We have recognized As of September 30, 2020, we held commodity contracts with a notional amount of $15.1 million. We previously designated all our commodity derivative contracts as cash flow hedges based on the nature of our business activities under the prior go-to-market strategy. As a result, all gains or losses associated with recording those commodity derivative contracts at fair value were recorded as a component of accumulated other comprehensive income (loss) (AOCI). We reclassify amounts from AOCI to cost of goods sold when we sell the underlying products to which those hedges relate. As of September 30, 2020, we expect the entire AOCI balance to be reclassified into earnings within the next three months. Certain amounts related to our hedging activities are as follows: Amount of Gain (Loss) Recognized in AOCI Amount of Gain (Loss) Reclassified to Earnings For the Nine Months Ended September 30, For the Nine Months Ended September 30, In thousands 2020 2019 2020 2019 Cash flow hedges: Commodity derivative contracts $ 8 $ — $ (28 ) $ — Foreign Exchange Risk Foreign currency fluctuations affect our foreign currency cash flows related primarily to payments to Cellectis. Our principal foreign currency exposure is to the euro. We do not hedge these exposures, and we do not believe that the current level of foreign currency risk is significant to our operations. Concentrations of Credit Risk We invest our cash, cash equivalents and restricted cash in highly liquid securities and investment funds and until late December 2019, also held deposits at a financial institution that exceeded insured limits. In the first quarter of 2020, we diversified this risk by shifting our investments to a diverse portfolio of short-dated, high investment-grade securities we classify as short-term investments that are recorded at fair value in our consolidated financial statements. We ensure the credit risk in this portfolio is in accordance with our internal policies and if necessary, make changes to investments to ensure credit risk is minimized. We have not experienced any counterparty credit losses.

Related-Party Transactions

Related-Party Transactions	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related-Party Transactions	3. RELATED-PARTY TRANSACTIONS We have several agreements that govern our relationship with Cellectis, some of which require us to make payments to Cellectis. Pursuant to our management services agreement with Cellectis, we incurred management fee expenses of $0.1 million for the three months ended September 30, 2020, and $0.3 million for the same period in 2019. We incurred management fee expenses of $0.2 million for nine months ended September 30, 2020, and $1.1 million for the same period in 2019. Cellectis has also guaranteed the lease agreement for our headquarters. Cellectis’ guarantee of our obligations under the lease will terminate at the end of the second consecutive calendar year in which our tangible net worth exceeds $300 million. TALEN ® ® ® for the three months ended September 30, 2020, and 2019. We incurred license and royalty fees of $0.1 million for the nine months ended September 30, 2020, and nominal fees for the same period in 2019. We have entered into various agreements with the University of Minnesota, pursuant to which we have been granted both exclusive and non-exclusive license agreements that carry annual license fees, milestone payments, royalties, and associated legal fees. These agreements primarily relate to gene-editing tools, enabling technologies and germplasm. We incurred nominal expenses pursuant to these agreements for the three and nine months ended September 30, 2020, and 2019.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Net Loss Per Share	4. NET LOSS PER SHARE Basic and diluted net loss per share was calculated using the following: Three Months Ended September 30, Nine Months Ended September 30, In Thousands, Except Share Data and Per Share Amounts 2020 2019 2020 2019 Net loss $ (9,476 ) $ (10,669 ) $ (31,441 ) $ (27,447 ) Weighted average shares outstanding - basic and diluted $ 33,200,289 $ 32,866,467 $ 33,076,376 $ 32,759,194 Basic and diluted net loss per share $ (0.29 ) $ (0.32 ) $ (0.95 ) $ (0.84 ) As of September 30, 2020 2019 Anti-dilutive stock options, restricted stock units, and performance stock units 5,581,307 5,688,399 All outstanding stock options, restricted stock units, and performance stock units are excluded from the calculation since they are anti-dilutive. We have not used the treasury method in determining the number of anti-dilutive stock options and restricted stock units in the table above.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	5. We use broad-based stock plans to attract and retain highly qualified officers and employees and to help ensure that management’s interests are aligned with those of our shareholders. We have also granted equity-based awards to directors, nonemployees, and certain employees of Cellectis. In December 2014, we adopted the Calyxt, Inc. Equity Incentive Plan (2014 Plan), which allowed for the grant of stock options, and in June 2017, we adopted the 2017 Omnibus Plan (2017 Plan), which allowed for the grant of stock options, performance shares and other types of equity awards. As of September 30, 2020, 1,223,547 shares were registered and available for grant under effective registration statements, while 3,905,316 shares were available for grant in the form of stock options, restricted stock, restricted stock units, and performance stock units under the 2017 Plan. Stock-based awards currently outstanding also include awards granted under the 2014 Plan, under which no further awards can be granted. Stock Options The estimated fair values of stock options granted, and the assumptions used for the Black-Scholes option pricing model were as follows: Nine Months Ended September 30, 2020 2019 Estimated fair values of stock options granted $ 3.32 $ 10.70 Assumptions: Risk-free interest rate 0.3%-1.7% 1.9%-2.5% Expected volatility 77.4%-81.2% 77.9%-78.9% Expected term (in years) 6.0-10.0 6.8-10.0 We estimate the fair value of each option on the grant date or other measurement dates if applicable using a Black-Scholes option-pricing model, which requires us to make predictive assumptions regarding future stock price volatility, employee exercise behavior and dividend yield. The risk-free interest rate for periods during the expected term of the options is based on the United States Treasury zero-coupon yield curve in effect at the date of grant. We estimate our future stock price volatility using the historical volatility of comparable public companies over the expected term of the option. Our expected term represents the period that options granted are expected to be outstanding determined using the simplified method. We have not paid dividends on our common stock and we do not currently plan to pay any cash dividends in the foreseeable future. Option strike prices are set at 100 percent or more of the closing share price on the date of grant, and generally vest over three to six years following the grant date. Options generally expire 10 years after the date of grant. Information on stock option activity is as follows: Options Exercisable Weighted- Average Exercise Price Per Share Options Outstanding Weighted- Average Exercise Price Per Share Balance as of December 31, 2019 1,789,567 $ 8.73 4,481,359 $ 11.73 Granted 800,265 4.78 Exercised (58,575 ) 3.60 Forfeited or expired (568,907 ) 14.92 Balance as of September 30, 2020 2,216,755 $ 9.94 4,654,142 $ 10.34 Stock-based compensation expense related to stock option awards is as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Stock-based compensation expense $ 187 $ 1,885 $ 2,439 $ 4,162 As of September 30, 2020, options outstanding and exercisable had an aggregate intrinsic value of $1.8 million and the weighted average remaining contractual term was 7.5 years. Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Net cash proceeds $ 211 $ 6 $ 211 $ 314 Intrinsic value of options exercised $ 179 $ 13 $ 179 $ 893 As of September 30, 2020, unrecognized compensation expense related to non-vested stock options was $8.7 million. This expense will be recognized over 32 months on average. Restricted Stock Units Units settled in stock subject to a restricted period may be granted under the 2017 Plan. Restricted stock units generally vest and become unrestricted over five years after the date of grant. Information on restricted stock unit activity is as follows: Number of Restricted Stock Units Outstanding Weighted- Average Grant Date Fair Value Unvested balance at December 31, 2019 813,526 $ 10.31 Granted 105,633 4.55 Vested (242,002 ) 9.38 Forfeited (61,659 ) 10.80 Unvested balance at September 30, 2020 615,498 $ 9.83 The total grant-date fair value of restricted stock unit awards that vested is as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Grant-date fair value $ 1,079 $ 392 $ 2,270 $ 1,803 Stock-based compensation expense related to restricted stock units is as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Stock-based compensation expense $ 269 $ 706 $ 865 $ 2,289 As of September 30, 2020, unrecognized compensation expense related to restricted stock units was $2.4 million. This expense will be recognized over 26 months on average. We treat stock-based compensation awards granted to employees of Cellectis as deemed dividends. We recorded deemed dividends as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Deemed dividends from grants to Cellectis employees $ 581 $ 296 $ 1,003 $ 1,072 Performance Stock Units In June 2019, we granted 311,667 performance stock units under the 2017 Plan to three executive officers. The performance stock units will vest at 50%, 100% or 120% of the shares under the award at the end of a three-year Stock-based compensation expense related to performance stock units is as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Stock-based compensation expense $ 114 $ 114 $ 334 $ 114 As of September 30, 2020, unrecognized compensation expense related to performance stock units was $1.6 million. This expense will be recognized over 45 months on average.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	6. INCOME TAXES We provide for a valuation allowance when it is more likely than not that we will not realize a portion of the deferred tax assets. We have established a full valuation allowance for deferred tax assets due to the uncertainty that enough taxable income will be generated in the taxing jurisdiction to utilize the assets. Therefore, we have not reflected any benefit of such deferred tax assets in the accompanying consolidated financial statements. As of September 30, 2020, there were no material changes to what we disclosed regarding tax uncertainties or penalties as of December 31, 2019.

Leases, Other Commitments, and

Leases, Other Commitments, and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Leases, Other Commitments, and Contingencies	7. LEASES, OTHER COMMITMENTS, AND CONTINGENCIES Litigation and Claims We are not currently a party to any material pending legal proceeding. Leases We lease our headquarters facility, office equipment, and other items. Our headquarters lease involved the sale of land and improvements to a third party who then constructed the facility. This lease is considered a financing lease. We also have an equipment financing arrangement that is considered a financing lease. This arrangement has a term of four years for each draw. We were required to deposit cash into a restricted account in an amount equal to the future rent payments required by the lease. As of September 30, 2020, restricted cash totaled $1.4 million. We have the option to request the return of excess collateral annually in December, and the amount we expect to receive is reflected as a current asset. Rent expense from operating leases was as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Rent expense from operating leases $ 24 $ 22 $ 71 $ 91 Other Commitments As of September 30, 2020, we have noncancelable commitments to purchase grain from farmers and seed from growers at dates throughout 2020 and 2021 aggregating $30.8 million based on current commodity futures market prices, other payments to growers, and estimated yields per acre. This amount is not recorded in the consolidated financial statements because we have not taken delivery of the grain as of September 30, 2020. If growers do not plant our soybeans, we allow the grain production contracts to be cancelled. Therefore, we do not include commitments to purchase grain as noncancelable commitment until the corresponding seed is planted.

Employee Benefit Plan

Employee Benefit Plan	9 Months Ended
	Sep. 30, 2020
Postemployment Benefits [Abstract]
Employee Benefit Plan	8. EMPLOYEE BENEFIT PLAN We provide a 401(k) defined contribution plan for all regular full-time employees who have completed two months of service. We match employee contributions up to certain amounts and those matching contributions vest immediately. Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Employee benefit plan expenses $ 63 $ 58 $ 261 $ 163

Supplemental Information

Supplemental Information	9 Months Ended
	Sep. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Information	9. SUPPLEMENTAL INFORMATION Certain balance sheet amounts are as follows: As of September 30, As of December 31, In Thousands 2020 2019 Accounts Receivable: Accounts receivable $ 1,074 $ 1,247 Receivables from growers 1,358 — Allowance for doubtful accounts — (125 ) Total $ 2,432 $ 1,122 We carry receivables related to amounts we are owed by growers from their purchases of seed. These amounts reduce the cost of the grain we ultimately purchase from the grower and are repaid either on current terms or on an extended payment basis. If a grower has elected extended payment terms they will pay a higher price per unit and grant us the right to deduct the amount we are owed from the payment we make upon the purchase of their grain. As of September 30, 2020, $1.2 million of the receivable from growers were on extended payment terms. As of December 31, 2019, this amount was zero. As of September 30, As of December 31, In Thousands 2020 2019 Inventory: Raw materials $ 4,097 $ 2,211 Work-in-process 341 272 Finished goods 1,515 111 Total $ 5,953 $ 2,594 Certain statements of operations amounts are as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Stock compensation expense: Research and development $ (84 ) $ 461 $ 723 $ 1,240 Selling and supply chain (372 ) 263 (472 ) 491 General and administrative 1,026 1,981 3,387 4,834 Total $ 570 $ 2,705 $ 3,638 $ 6,565 Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Interest, net: Interest expense $ (369 ) $ (374 ) $ (1,112 ) $ (1,114 ) Interest income 45 406 544 1,410 Total $ (324 ) $ 32 $ (568 ) $ 296 Certain statements of cash flows amounts are as follows: As of September 30, In Thousands 2020 2019 Cash, cash equivalents, restricted cash, and short-term investments: Cash and cash equivalents $ 7,170 $ 66,434 Restricted cash 1,434 1,516 Total cash, cash equivalents, and restricted cash 8,604 67,950 Short-term investments 20,802 — Total cash, cash equivalents, restricted cash, and short-term investments $ 29,406 $ 67,950 Nine Months Ended September 30, In Thousands 2020 2019 Supplemental cash flow information: Interest paid $ 1,097 $ 1,108

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Segment Information	10. SEGMENT INFORMATION We operate in a single

Long-Term Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Long-Term Debt	11. LONG-TERM DEBT Our long-term debt is comprised of a $1.5 million promissory note pursuant to the Paycheck Protection Program (the Paycheck Protection Program loan) established by the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) implemented by the U.S. Small Business Administration (SBA). We received the funds under the Paycheck Protection Program loan on April 19, 2020. The Paycheck Protection Program loan matures in April 2022 and bears interest at a per annum rate of 1.00%. The Paycheck Protection Program loan may be prepaid at any time prior to maturity with no prepayment penalties. The Paycheck Protection Program loan contains customary events of default relating to, among other things, payment defaults and breaches of representations and warranties. Subject to certain conditions, the Paycheck Protection Program loan and accrued interest may be forgiven in whole or in part by applying for forgiveness pursuant to the CARES Act and the Paycheck Protection Program. In order to be eligible for forgiveness, the proceeds of the Paycheck Protection Program loan must be applied to certain eligible expenses, including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments, with not more than 40% of the amount applied to non-payroll costs. We have applied the proceeds from the Paycheck Protection Program loan toward qualifying expenses and on October 21, 2020, applied

Restructuring Costs

Restructuring Costs	9 Months Ended
	Sep. 30, 2020
Restructuring And Related Activities [Abstract]
Restructuring Costs	12. RESTRUCTURING COSTS On August 4, 2020, we approved the advancement of our soybean products to a streamlined go-to-market strategy. The impact of the advancement included staffing adjustments related to soybean processing and product sales, as well as the gradual exit of all supply chain contractual commitments that are not associated with the ongoing soybean seed go-to-market strategy. In the three months ended September 30, 2020, we recorded $0.4 million of cash charges for severance and other related payments, and we also recorded a $0.9 million recapture benefit of non-cash stock compensation expense from of unvested stock awards. We expect to record up to $0.3 million of through the second quarter of 2021 0.6 . The following table presents the restructuring and severance cost liabilities as of September 30, 2020: As of September 30, In Thousands 2020 Balance at June 30, 2020 $ — Charged to expense 436 Cash payments (175 ) Balance as of September 30, 2020 $ 261 The September 30, 2020, liability balance of $0.3 million as well as up to an additional $0.3 million of severance and other related expenses yet to be recorded are expected to be paid through the second quarter of fiscal 2021.

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Event	13. SUBSEQUENT EVENT On October 20, 2020, we completed a $15.0 million equity financing transaction through an SEC-registered, direct offering of our common stock pursuant to our existing Form S-3 shelf registration statement filed with the SEC on August 13, 2019. The net proceeds of the offering were

Basis of Presentation & Summa_2

Basis of Presentation & Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Short-term investments	Short-term investments We consider investments with more than ninety days to maturity at issuance to be short-term investments. These short-term investments are considered trading securities and are carried at fair value with any unrealized gains and losses recorded in current earnings as a component of interest, net.
Revenue Recognition	Revenue Recognition In certain instances, we may sell grain to a processor with a commitment to repurchase any soybean meal resulting from their grain crushing activity with a single net cash settlement occurring between the parties. In those instances, we recognize revenue from the sale of grain in the amount of the final net cash settlement with the processor. We also recognize revenue on our sale of the meal to our customers in accordance with our previously disclosed revenue recognition accounting policies. Costs are ascribed to grain and meal sold pursuant to the agreement with the processor.

Financial Instruments, Measur_2

Financial Instruments, Measured at Fair Value, Hedging Activities, and Concentrations of Credit Risk (Tables)	9 Months Ended
	Sep. 30, 2020
Text Block [Abstract]
Summary of Fair Value Measurements and Financial Statement Presentation	The fair values of our financial instruments measured at fair value and their respective levels in the fair value hierarchy as of September 30, 2020, and December 31, 2019, were as follows: September 30, 2020 September 30, 2020 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Short-term investments $ 20,802 $ — $ — $ 20,802 $ — $ — $ — $ — Commodity derivative contracts 132 — — 132 — — — — Total $ 20,934 $ — $ — $ 20,934 $ — $ — $ — $ — December 31, 2019 December 31, 2019 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Commodity derivative contracts $ 62 $ — $ — $ 62 $ — $ — $ — $ — Total $ 62 $ — $ — $ 62 $ — $ — $ — $ —
Composition of Short-term Investments	The composition of our short-term investments as of September 30, 2020, and December 31, 2019 were as follows: As of September 30, As of December 31, In Thousands 2020 2019 Corporate debt securities $ 17,803 $ — Commercial paper 2,999 — Total $ 20,802 $ —
Summary of Certain Amounts Related to Hedging Activities	Certain amounts related to our hedging activities are as follows: Amount of Gain (Loss) Recognized in AOCI Amount of Gain (Loss) Reclassified to Earnings For the Nine Months Ended September 30, For the Nine Months Ended September 30, In thousands 2020 2019 2020 2019 Cash flow hedges: Commodity derivative contracts $ 8 $ — $ (28 ) $ —

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	Basic and diluted net loss per share was calculated using the following: Three Months Ended September 30, Nine Months Ended September 30, In Thousands, Except Share Data and Per Share Amounts 2020 2019 2020 2019 Net loss $ (9,476 ) $ (10,669 ) $ (31,441 ) $ (27,447 ) Weighted average shares outstanding - basic and diluted $ 33,200,289 $ 32,866,467 $ 33,076,376 $ 32,759,194 Basic and diluted net loss per share $ (0.29 ) $ (0.32 ) $ (0.95 ) $ (0.84 ) As of September 30, 2020 2019 Anti-dilutive stock options, restricted stock units, and performance stock units 5,581,307 5,688,399

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Fair Values of Stock Options Granted and Assumptions used in Black-Scholes Model	The estimated fair values of stock options granted, and the assumptions used for the Black-Scholes option pricing model were as follows: Nine Months Ended September 30, 2020 2019 Estimated fair values of stock options granted $ 3.32 $ 10.70 Assumptions: Risk-free interest rate 0.3%-1.7% 1.9%-2.5% Expected volatility 77.4%-81.2% 77.9%-78.9% Expected term (in years) 6.0-10.0 6.8-10.0
Summary of Stock Option Activity	Information on stock option activity is as follows: Options Exercisable Weighted- Average Exercise Price Per Share Options Outstanding Weighted- Average Exercise Price Per Share Balance as of December 31, 2019 1,789,567 $ 8.73 4,481,359 $ 11.73 Granted 800,265 4.78 Exercised (58,575 ) 3.60 Forfeited or expired (568,907 ) 14.92 Balance as of September 30, 2020 2,216,755 $ 9.94 4,654,142 $ 10.34
Schedule of Net Cash Proceeds from Exercise of Stock Options Less Shares Used for Minimum Withholding Taxes and Intrinsic Value of Options Exercised	Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Net cash proceeds $ 211 $ 6 $ 211 $ 314 Intrinsic value of options exercised $ 179 $ 13 $ 179 $ 893
Summary of Activity of Restricted Stock Units	Information on restricted stock unit activity is as follows: Number of Restricted Stock Units Outstanding Weighted- Average Grant Date Fair Value Unvested balance at December 31, 2019 813,526 $ 10.31 Granted 105,633 4.55 Vested (242,002 ) 9.38 Forfeited (61,659 ) 10.80 Unvested balance at September 30, 2020 615,498 $ 9.83
Summary of Grant Date Fair Value of Restricted Stock Unit Awards Vested	The total grant-date fair value of restricted stock unit awards that vested is as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Grant-date fair value $ 1,079 $ 392 $ 2,270 $ 1,803
Summary of Stock-Based Compensation Granted As Deemed Dividends	We treat stock-based compensation awards granted to employees of Cellectis as deemed dividends. We recorded deemed dividends as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Deemed dividends from grants to Cellectis employees $ 581 $ 296 $ 1,003 $ 1,072
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock-based Compensation Expense	Stock-based compensation expense related to stock option awards is as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Stock-based compensation expense $ 187 $ 1,885 $ 2,439 $ 4,162
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock-based Compensation Expense	Stock-based compensation expense related to restricted stock units is as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Stock-based compensation expense $ 269 $ 706 $ 865 $ 2,289
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock-based Compensation Expense	Stock-based compensation expense related to performance stock units is as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Stock-based compensation expense $ 114 $ 114 $ 334 $ 114

Leases, Other Commitments, an_2

Leases, Other Commitments, and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2020
Lease Cost [Abstract]
Summary of Rent Expense from Operating Leases	Rent expense from operating leases was as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Rent expense from operating leases $ 24 $ 22 $ 71 $ 91

Employee Benefit Plan (Tables)

Employee Benefit Plan (Tables)	9 Months Ended
	Sep. 30, 2020
Postemployment Benefits [Abstract]
Summary of Defined Contribution Plan	Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Employee benefit plan expenses $ 63 $ 58 $ 261 $ 163

Supplemental Information (Table

Supplemental Information (Tables)	9 Months Ended
	Sep. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Certain Balance Sheet Amounts	Certain balance sheet amounts are as follows: As of September 30, As of December 31, In Thousands 2020 2019 Accounts Receivable: Accounts receivable $ 1,074 $ 1,247 Receivables from growers 1,358 — Allowance for doubtful accounts — (125 ) Total $ 2,432 $ 1,122 We carry receivables related to amounts we are owed by growers from their purchases of seed. These amounts reduce the cost of the grain we ultimately purchase from the grower and are repaid either on current terms or on an extended payment basis. If a grower has elected extended payment terms they will pay a higher price per unit and grant us the right to deduct the amount we are owed from the payment we make upon the purchase of their grain. As of September 30, 2020, $1.2 million of the receivable from growers were on extended payment terms. As of December 31, 2019, this amount was zero. As of September 30, As of December 31, In Thousands 2020 2019 Inventory: Raw materials $ 4,097 $ 2,211 Work-in-process 341 272 Finished goods 1,515 111 Total $ 5,953 $ 2,594
Schedule of Certain Statements of Operations Amounts	Certain statements of operations amounts are as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Stock compensation expense: Research and development $ (84 ) $ 461 $ 723 $ 1,240 Selling and supply chain (372 ) 263 (472 ) 491 General and administrative 1,026 1,981 3,387 4,834 Total $ 570 $ 2,705 $ 3,638 $ 6,565 Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2020 2019 2020 2019 Interest, net: Interest expense $ (369 ) $ (374 ) $ (1,112 ) $ (1,114 ) Interest income 45 406 544 1,410 Total $ (324 ) $ 32 $ (568 ) $ 296
Schedule of Statements of Certain Statements of Cash Flows Amounts	Certain statements of cash flows amounts are as follows: As of September 30, In Thousands 2020 2019 Cash, cash equivalents, restricted cash, and short-term investments: Cash and cash equivalents $ 7,170 $ 66,434 Restricted cash 1,434 1,516 Total cash, cash equivalents, and restricted cash 8,604 67,950 Short-term investments 20,802 — Total cash, cash equivalents, restricted cash, and short-term investments $ 29,406 $ 67,950 Nine Months Ended September 30, In Thousands 2020 2019 Supplemental cash flow information: Interest paid $ 1,097 $ 1,108

Restructuring Costs (Tables)

Restructuring Costs (Tables)	9 Months Ended
	Sep. 30, 2020
Restructuring And Related Activities [Abstract]
Summary of Restructuring and Severance Cost Liabilities	The following table presents the restructuring and severance cost liabilities as of September 30, 2020: As of September 30, In Thousands 2020 Balance at June 30, 2020 $ — Charged to expense 436 Cash payments (175 ) Balance as of September 30, 2020 $ 261

Financial Instruments, Measur_3

Financial Instruments, Measured at Fair Value, Hedging Activities, and Concentrations of Credit Risk - Summary of Fair Value Measurements and Financial Statement Presentation (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	$ 20,934	$ 62
Short Term Investments [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	20,802
Commodity Derivative Contracts [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	132	62
Level 1 [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	20,934	62
Level 1 [Member] | Short Term Investments [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	20,802
Level 1 [Member] | Commodity Derivative Contracts [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	$ 132	$ 62

Financial Instruments, Measur_4

Financial Instruments, Measured at Fair Value, Hedging Activities, and Concentrations of Credit Risk - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair value of financing leases	$ 15.2	$ 15.2	$ 15.7
Commodity Contracts [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Commodity derivative assets, notional amount	15.1	15.1
Commodity derivative losses from hedging contracts sold, amount recognized	$ 1.1	$ 1.1

Financial Instruments, Measur_5

Financial Instruments, Measured at Fair Value, Hedging Activities, and Concentrations of Credit Risk - Composition of Short-term Investments (Detail) $ in Thousands	Sep. 30, 2020USD ($)
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Total short-term investments	$ 20,802
Corporate Debt Securities [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Total short-term investments	17,803
Commercial Paper [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Total short-term investments	$ 2,999

Financial Instruments, Measur_6

Financial Instruments, Measured at Fair Value, Hedging Activities, and Concentrations of Credit Risk - Summary of Certain Amounts Related to Hedging Activities (Detail) - Commodity Derivative Contracts [Member] - Cash Flow Hedges [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Amount of Gain (Loss) Recognized in AOCI	$ 8
Amount of Gain (Loss) Reclassified to Earnings	$ (28)

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail) - Cellectis [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Related Party Transaction [Line Items]
Minimum net worth required	$ 300,000,000		$ 300,000,000
General and Administrative Expense [Member]
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party	$ 100,000	$ 300,000	200,000	$ 1,100,000
License and Royalty Fees [Member]
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party			$ 100,000

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
Net loss	$ (9,476)	$ (10,669)	$ (31,441)	$ (27,447)
Weighted average shares outstanding - basic and diluted	33,200,289	32,866,467	33,076,376	32,759,194
Basic and diluted net loss per share	$ (0.29)	$ (0.32)	$ (0.95)	$ (0.84)
Anti-dilutive stock options, restricted stock units, and performance stock units			5,581,307	5,688,399

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail)	Sep. 30, 2020shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares registered and available for grant	1,223,547
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares registered and available for grant	3,905,316

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Fair Values of Stock Options Granted and Assumptions used in Black-Scholes Model (Detail) - Stock Options [Member] - $ / shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair values of stock options granted	$ 3.32	$ 10.70
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.30%	1.90%
Expected volatility	77.40%	77.90%
Expected term (in years)	6 years	6 years 9 months 18 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.70%	2.50%
Expected volatility	81.20%	78.90%
Expected term (in years)	10 years	10 years

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Options - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2020USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to non-vested stock options	$ 8,700,000
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options priced at fair market value, percent	100.00%
Stock option expiration period	10 years
Weighted average remaining contractual term	7 years 6 months
Aggregate intrinsic value of options outstanding and exercisable	$ 1,800,000
2017 Omnibus Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, vesting period	3 years
2017 Omnibus Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, vesting period	6 years
Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividends paid on common stock	$ 0
Unrecognized stock-based compensation expense, expected recognition weighted-average period	32 months

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock Option Activity (Detail)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options Exercisable, Beginning Balance | shares	1,789,567
Options Exercisable, Ending Balance | shares	2,216,755
Weighted-Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 8.73
Weighted-Average Exercise Price Per Share, Ending Balance | $ / shares	$ 9.94
Options Outstanding, Beginning Balance | shares	4,481,359
Options Outstanding, Granted | shares	800,265
Options Outstanding, Exercised | shares	(58,575)
Options Outstanding, Forfeited or expired | shares	(568,907)
Options Outstanding, Ending Balance | shares	4,654,142
Weighted-Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 11.73
Weighted-Average Exercise Price Per Share, Granted | $ / shares	4.78
Weighted-Average Exercise Price Per Share, Exercised | $ / shares	3.60
Weighted-Average Exercise Price Per Share, Forfeited or expired | $ / shares	14.92
Weighted-Average Exercise Price Per Share, Ending Balance | $ / shares	$ 10.34

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock-Based Compensation Expense Related to Stock Option Awards (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 570	$ 2,705	$ 3,638	$ 6,565
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 187	$ 1,885	$ 2,439	$ 4,162

Stock-Based Compensation - Su_4

Stock-Based Compensation - Summary of Net Cash Proceeds from Exercise of Stock Options Less Shares Used for Minimum Withholding Taxes and Intrinsic Value of Options Exercised (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Net cash proceeds	$ 211	$ 6	$ 211	$ 314
Intrinsic value of options exercised	$ 179	$ 13	$ 179	$ 893

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units - Additional Information (Detail) - Restricted Stock Units [Member] $ in Millions	9 Months Ended
	Sep. 30, 2020USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to restricted stock units	$ 2.4
Unrecognized stock-based compensation expense, expected recognition weighted-average period	26 months
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years

Stock-Based Compensation - Su_5

Stock-Based Compensation - Summary of Activity of Restricted Stock Units (Detail) - Restricted Stock Units [Member]	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock units outstanding, Unvested beginning balance | shares	813,526
Number of restricted stock units outstanding, Granted | shares	105,633
Number of restricted stock units outstanding, Vested | shares	(242,002)
Number of restricted stock units outstanding, Forfeited | shares	(61,659)
Number of restricted stock units outstanding, Unvested ending balance | shares	615,498
Weighted-average grant date fair value, Unvested beginning balance | $ / shares	$ 10.31
Weighted-average grant date fair value, Granted | $ / shares	4.55
Weighted-average grant date fair value, Vested | $ / shares	9.38
Weighted-average grant date fair value, Forfeited | $ / shares	10.80
Weighted-average grant date fair value, Unvested ending balance | $ / shares	$ 9.83

Stock-Based Compensation - Su_6

Stock-Based Compensation - Summary of Grant Date Fair Value of Restricted Stock Unit Awards Vested (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant-date fair value	$ 1,079	$ 392	$ 2,270	$ 1,803

Stock-Based Compensation - Su_7

Stock-Based Compensation - Summary of Stock-Based Compensation Expenses Related to Restricted Stock Units (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 570	$ 2,705	$ 3,638	$ 6,565
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 269	$ 706	$ 865	$ 2,289

Stock-Based Compensation - Su_8

Stock-Based Compensation - Summary of Stock-Based Compensation Granted as Deemed Dividends (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Nonemployee Restricted Stock Units [Member] | Cellectis [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deemed dividends from grants to Cellectis employees	$ 581	$ 296	$ 1,003	$ 1,072

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance Stock Units - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	9 Months Ended
	Jun. 30, 2019	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted		1,223,547
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted		3,905,316
Performance Stock Units [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Increase in common stock starting price	$ 12.48
Unrecognized stock-based compensation expense related to performance stock units		$ 1.6
Unrecognized stock-based compensation expense, expected recognition weighted-average period		45 months
Performance Stock Units [Member] | Tranche One [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	50.00%
Performance Stock Units [Member] | Tranche Two [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	100.00%
Performance Stock Units [Member] | Tranche Three [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	120.00%
Performance Stock Units [Member] | Three Executive Officers [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted	311,667

Stock-Based Compensation - Su_9

Stock-Based Compensation - Summary of Stock-Based Compensation Expenses Related to Performance Stock Units (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 570	$ 2,705	$ 3,638	$ 6,565
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 114	$ 114	$ 334	$ 114

Leases, Other Commitments, an_3

Leases, Other Commitments, and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Other Commitments [Line Items]
Restricted cash	$ 1,434	$ 1,516
Forward purchase noncancelable commitments amount	$ 30,800
Equipment [Member]
Other Commitments [Line Items]
Lease term	4 years
Restricted cash	$ 1,400

Leases, Other Commitments, an_4

Leases, Other Commitments, and Contingencies - Summary of Rent Expense from Operating Leases (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating Leases Rent Expense [Abstract]
Rent expense from operating leases	$ 24	$ 22	$ 71	$ 91

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2020
Compensation Related Costs [Abstract]
Defined contribution plan description	We provide a 401(k) defined contribution plan for all regular full-time employees who have completed two months of service.

Employee Benefit Plan - Summary

Employee Benefit Plan - Summary of Defined Contribution Plan (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Compensation And Retirement Disclosure [Abstract]
Employee benefit plan expenses	$ 63	$ 58	$ 261	$ 163

Supplemental Information - Summ

Supplemental Information - Summary of Certain Balance Sheet Amounts (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Accounts Receivable:
Accounts receivable	$ 1,074	$ 1,247
Allowance for doubtful accounts		(125)
Total	2,432	1,122
Inventory:
Raw materials	4,097	2,211
Work-in-process	341	272
Finished goods	1,515	111
Total	5,953	$ 2,594
Growers [Member]
Accounts Receivable:
Accounts receivable	$ 1,358

Supplemental Information - Addi

Supplemental Information - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Condensed Balance Sheet Statements Captions [Line Items]
Receivable from growers	$ 1,074	$ 1,247
Growers [Member]
Condensed Balance Sheet Statements Captions [Line Items]
Receivable from growers	1,358
Growers [Member] | Extended Payment Terms [Member]
Condensed Balance Sheet Statements Captions [Line Items]
Receivable from growers	$ 1,200	$ 0

Supplemental Information - Su_2

Supplemental Information - Summary of Certain Statements of Operations Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	$ 570	$ 2,705	$ 3,638	$ 6,565
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	(84)	461	723	1,240
Selling and Supply Chain [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	(372)	263	(472)	491
General and Administrative Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	$ 1,026	$ 1,981	$ 3,387	$ 4,834

Supplemental Information - Su_3

Supplemental Information - Summary of Components of Interest, Net (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Interest expense	$ (369)	$ (374)	$ (1,112)	$ (1,114)
Interest income	45	406	544	1,410
Total	$ (324)	$ 32	$ (568)	$ 296

Supplemental Information - Su_4

Supplemental Information - Summary of Statements of Certain Statements of Cash Flows Amounts (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Cash and cash equivalents	$ 7,170	$ 66,434	$ 58,610
Restricted cash	1,434	1,516
Total cash, cash equivalents, and restricted cash	8,604	67,950	$ 60,038	$ 95,288
Short-term investments	20,802
Total cash, cash equivalents, restricted cash, and short-term investments	29,406	67,950
Interest paid	$ 1,097	$ 1,108

Segment Information - Additiona

Segment Information - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2020Segment
Segment Reporting [Abstract]
Number of reportable segments	1

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail) - Paycheck Protection Program Loan CARES Act [Member] - USD ($)	Apr. 19, 2020	Sep. 30, 2020
Debt Instrument [Line Items]
Loan, face amount	$ 1,500,000
Loan, interest rate	1.00%
Loan, maturity date	2022-04
Prepayment penalties	$ 0
Forgiveness eligibility description		In order to be eligible for forgiveness, the proceeds of the Paycheck Protection Program loan must be applied to certain eligible expenses, including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments, with not more than 40% of the amount applied to non-payroll costs.

Restructuring Costs - Additiona

Restructuring Costs - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
Restructuring Costs [Abstract]
Severance and other charges	$ 436,000
Stock-based compensation		$ 3,638,000	$ 6,565,000
Restructuring and severance cost liabilities	261,000	261,000
Soybean Products [Member]
Restructuring Costs [Abstract]
Severance and other charges	400,000
Stock-based compensation	900,000
Restructuring and severance cost liabilities	300,000	300,000
Soybean Products [Member] | Employee Severance and Other Related Payments [Member] | Maximum [Member]
Restructuring Costs [Abstract]
Restructuring and related cost, expected cost remaining	300,000	300,000
Soybean Products [Member] | Transitional Expenses [Member]
Restructuring Costs [Abstract]
Restructuring and related cost, expected cost remaining	$ 600,000	$ 600,000

Restructuring Costs - Summary o

Restructuring Costs - Summary of Restructuring and Severance Cost Liabilities (Detail) $ in Thousands	3 Months Ended
	Sep. 30, 2020USD ($)
Restructuring And Related Activities [Abstract]
Charged to expense	$ 436
Cash payments	(175)
Balance as of September 30, 2020	$ 261

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - Subsequent Event [Member] $ in Millions	Oct. 20, 2020USD ($)
Subsequent Event [Line Items]
Equity financing transaction value	$ 15
Net proceeds from equity financing transaction	$ 14